NCT00047320 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 104
- units
- Participants
- groups
- description
- Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \> 750/L and platelets \> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy. carboplatin: Given IV etoposide: Given IV ifosfamide: Given IV radiation therapy: craniospinal irradiation
- id
- BG000
- title
- Radiation Therapy (CR From Induction)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 3
- upper Limit
- 23
- value
- 12
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- title
- Female
- measurements
- group Id
- BG000
- value
- 79
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 8
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 72
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 12
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 85
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 88
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 10
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 104
- units
- Participants
- groups
- description
- Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \> 750/L and platelets \> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy. carboplatin: Given IV etoposide: Given IV ifosfamide: Given IV radiation therapy: craniospinal irradiation
- id
- BG000
- title
- Radiation Therapy (CR From Induction)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 3
- upper Limit
- 23
- value
- 12
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- title
- Female
- measurements
- group Id
- BG000
- value
- 79
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 8
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 72
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 12
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 85
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 88
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 10
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 5
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle